Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines

Ann Oncol. 2017 Jul 1;28(suppl_4):iv100-iv118. doi: 10.1093/annonc/mdx216.

Authors

S Roselló¹, I Blasco¹, L García Fabregat¹, A Cervantes¹, K Jordan²; ESMO Guidelines Committee

Affiliations

¹ Medical Oncology Department, CIBERONC, Biomedical Research Institute INCLIVA, Valencia, Spain.
² Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany.

PMID: 28881914
DOI: 10.1093/annonc/mdx216

No abstract available

Publication types

Practice Guideline

MeSH terms

Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects*
Drug-Related Side Effects and Adverse Reactions / etiology*
Drug-Related Side Effects and Adverse Reactions / therapy*
Humans
Infusions, Intravenous / adverse effects
Infusions, Intravenous / methods
Medical Oncology / standards*
Neoplasms / drug therapy

Substances

Antineoplastic Agents